DERENOFYLLINE

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C18H20N4O
Molecular Weight	308.3776
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O[C@H]1CC[C@@H](CC1)NC2=NC(=NC3=C2C=CN3)C4=CC=CC=C4

InChI

InChIKey=RBZNJGHIKXAKQE-HDJSIYSDSA-N

InChI=1S/C18H20N4O/c23-14-8-6-13(7-9-14)20-18-15-10-11-19-17(15)21-16(22-18)12-4-2-1-3-5-12/h1-5,10-11,13-14,23H,6-9H2,(H2,19,20,21,22)/t13-,14-

HIDE SMILES / InChI

Molecular Formula	C18H20N4O
Molecular Weight	308.3776
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19639278
Curator's Comment: description was created based on several sources, including: http://adisinsight.springer.com/drugs/800016704 | https://www.ncbi.nlm.nih.gov/pubmed/17558436 |

Derenofyllin (SLV320) is a selective adenosine A1 receptor antagonist, which is under investigation for the treatment of heart failure with renal dysfunction. Adverse events considered related to SLV320 were dizziness, nausea, transient hypertension and transient hypotension.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Adenosine A1 receptor 54 Target ID: CHEMBL226 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17558436	Antagonist 2849		9.0 null [pKi]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Acute heart failure 9 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19919976 https://www.ncbi.nlm.nih.gov/pubmed/21641345	Primary		Phase II 1147	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
245 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19919976	15 mg single, intravenous dose: 15 mg route of administration: Intravenous experiment type: SINGLE co-administered:		DERENOFYLLINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
144 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19919976	10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered:		DERENOFYLLINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
427 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19919976	15 mg single, intravenous dose: 15 mg route of administration: Intravenous experiment type: SINGLE co-administered:		DERENOFYLLINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
235 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19919976	10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered:		DERENOFYLLINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.13 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19919976	15 mg single, intravenous dose: 15 mg route of administration: Intravenous experiment type: SINGLE co-administered:		DERENOFYLLINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19919976	10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered:		DERENOFYLLINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
15 mg 2 times / day multiple, intravenous Highest studied dose Dose: 15 mg, 2 times / day Route: intravenous Route: multiple Dose: 15 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21641345	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/21641345	Sources: https://pubmed.ncbi.nlm.nih.gov/21641345
15 mg single, intravenous Highest studied dose Dose: 15 mg Route: intravenous Route: single Dose: 15 mg Sources: https://pubmed.ncbi.nlm.nih.gov/19919976	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/19919976	Sources: https://pubmed.ncbi.nlm.nih.gov/19919976

Sourcing

Vendor/Aggregator	ID	URL
MuseChem	I006358	https://www.musechem.com/product/I006358.html
Wonderchem	WD05PUC	http://www.wonder-chem.com/search.html?text=WD05PUC

PubMed

Title	Date	PubMed
Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.	2009-11	19919976
A1 adenosine receptor antagonists, agonists, and allosteric enhancers.	2009	19639278
The adenosine A1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure.	2007-08	17558436

Patents

Sample Use Guides

In Vivo Use Guide

1-hour infusion of 5, 10, and 15 mg SLV320

Route of Administration: Intravenous

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:41:44 GMT 2025` Edited by `admin` on `Mon Mar 31 18:41:44 GMT 2025`
Record UNII	O1Q96UZ63W
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SLV-320

Preferred Name

English

DERENOFYLLINE

Official Name

English

CYCLOHEXANOL, 4-((2-PHENYL-7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)AMINO)-, TRANS-

Systematic Name

English

TRANS-4-((2-PHENYL-7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)AMINO)CYCLOHEXANOL

Systematic Name

English

derenofylline [INN]

Common Name

English

SLV320

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C319